An interventional study of RecoVRy and VR Games in Psychosis, sponsored by Oslo University Hospital. Recruiting at 2 sites in Norway. Open to participants aged 17 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-25.
Sponsored by Oslo University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Psychotic Disorders with a site in Norway — 6 open to participants now, 7 under way, none of them phase 3. Psychotic Disorders · Norway.
Among the 26 studies in Psychotic Disorders with a site in Norway, this one is the 6th largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2024, is one of 12 with no phase, and was the 25th registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
Browse Psychotic Disorders studies →6 of the 26 studies in Psychotic Disorders with a site in Norway are open now. Recruiting first, the newest first:
Philipp Homan · Sites in Norway, Czechia, Ireland and 3 more countries
Ages 18–65 · Healthy volunteers
Haukeland University Hospital · Sites in Norway
Ages 16+
Vestre Viken Hospital Trust · Sites in Norway
Ages 18+
Sykehuset i Vestfold HF · Sites in Norway
Ages 18–65
Oslo University Hospital · Sites in Norway
Ages 18–95
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 17 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 2 · Phase 4 4
First in 2001; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 65 across 1,326 interventional studies indexed under Psychotic Disorders.
Median enrollment 87 across the 20 interventional studies, 211 across the 6 observational. Of the 16 that completed or were terminated, 3 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 26 have an industry lead sponsor. The 10 most frequent:
Oslo University Hospital is the lead sponsor of 835 studies on the registry; 148 are open to participants now.
Oslo University Hospital has 7 studies filed under Psychotic Disorders — fewer than ten, so there is no comparison to draw.
1 of the studies in Psychotic Disorders with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05719116Solli Distriktspsykiatriske SenterA Combined Aerobic and Resistance Training Program for Adults With Psychotic Disorders | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Psychotic Disorders with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Virtual Reality (VR) has gained momentum in the treatment of various mental health conditions. Despite its potential and emphasis on better use of technology in healthcare strategies, VR therapy for severe mental illness remains underdeveloped and understudied. This will be the first randomized controlled trial to combine cognitive behavioral therapy-based VR with state-of-the-art Artificial Intelligence. Reduced quality of life, social withdrawal and inactivity found in psychotic disorders may be largely explained by avoidance due to severe symptoms of anxiety, present in as many as two-thirds of patients with schizophrenia. Alleviating anxiety may thus be key to help improve functional outcomes. The aim of this study is to provide novel information about VR therapy in psychosis employing the newly developed RecoVRy application. Study objectives are to examine short- and long-term effects on real-world functioning, psychiatric symptoms, and quality of life. A total of 150 participants will be recruited from five Norwegian hospitals. Participants will be randomly assigned to either receive the RecoVRy intervention (N=75) alongside treatment as usual or a control intervention (N=75) in which they engage with three distinct VR games. RecoVRy will generate new and important knowledge to improve mental health services in psychosis and hopefully improve existing practise and facilitate personalized treatment. RecoVRy will fill knowledge gaps concerning anxiety in psychosis, as this is often left untreated and consequently create societal benefits by increasing social and functional participation. Finally, knowledge from RecoVRy can easily be generalized to other patient groups and health sectors.
Introduction Virtual Reality (VR) immerses people in digitally simulated environments that can provide exciting interactive experiences and is thus well established in the entertainment industry. VR is however not just about fun and games; therapeutic use of VR is becoming increasingly popular for a broad range of mental health conditions such as anxiety disorders, PTSD, phobias and chronic pain. Although the concept of VR as a treatment modality has gained momentum and (better) use of technology is an explicitly stated goal in health care strategies and guidelines, the use of VR therapy in severe mental illness is much less developed and has received less attention. The important question therefore arises whether VR therapy actually improves clinical and functional outcome in psychosis and whether it is cost-effective. The RecoVRy study will answer these questions in the first randomized controlled trial (RCT) combining virtual reality with state-of-the-art Artificial Intelligence (AI). A strong multidisciplinary team of researchers and clinicians (psychiatry, clinical psychology, health economy, digital health, and occupational therapy) will run this RCT in close collaboration with a world-renowned expert on VR therapy in psychosis.
Schizophrenia and psychotic disorders Psychotic disorders are rare, with a lifetime prevalence close to 1 %. Still, they impose a major burden of illness in terms of both individual suffering and societal cost. They are severe and often chronic mental disorders characterized by a heterogenic set of positive and negative psychotic symptoms, neurocognitive impairment, and functional decline. Total costs associated with schizophrenia spectrum disorders in Norway are estimated to approximately 10.2 billion NOK per year making it the 5th most expensive health condition, with indirect cost due to productivity loss accounting for as much as 30 % and only between 5 % - 10 % having paid employment. Despite increased etiological understanding and refined treatment approaches, today's standard psychosis treatment does not prevent a large proportion of individuals with schizophrenia becoming isolated and inactive, which in turn negatively affects both physical and mental health. Individuals with schizophrenia are estimated to lose 13 - 15 years of potential life years. Reduced quality of life, social withdrawal and inactivity may largely be explained by avoidance due to symptoms of anxiety. As many as two-thirds of patients with schizophrenia have levels of anxious avoidance equivalent to those in individuals with agoraphobia. Symptoms of anxiety emerge for different reasons; hallucinations, fear of rejection, harm or social humiliation, paranoia, social inexperience, and risk of stigma, and may contribute significantly to the functional impairment observed in schizophrenia. Alleviating anxiety symptoms may thus be key to help improve functional outcomes and tackle the serious issues of social withdrawal and inactivity in individuals with schizophrenia.
Whilst the effect of antipsychotic medication in reducing positive psychotic symptoms and risk of relapse is well-documented, non-response and poor adherence to antipsychotic medication is frequent. Furthermore, negative symptoms are often associated with a limited response to pharmacotherapy. Cognitive Behavioral Therapy for psychosis (CBTp) is an established psychotherapeutic intervention recommended in several international and national guidelines. Meta-analyses have reported small effects of CBTp on psychotic symptoms, and there is considerable room for improvement. It has been suggested that an increased focus on the behavioral component of CBT, using repeated behavioral experiments, behavioral activation and exposure, may increase the effect of CBTp. Virtual Reality facilitates exactly that; a greater focus on behavioural aspects of CBTp.
System-level factors also challenge the delivery of appropriate psychological treatments such as CBTp. Mental health services worldwide are faced with increased patient contact volume and clinician caseload size. Implementing CBTp requires resources often not present in the mental health system. It warrants therapists' education, a certain training volume, adherence to treatment and above all exposure and learning in real-world situations. Typically, clinicians have little to no time to accompany patients in sessions outside the clinic. This imbalance between demand and supply of mental health services underlines the need for an intervention directly addressing these issues, such as the RecoVRy study to bridge this gap.
Virtual Reality Exposure Therapy (VRET) VRET is a promising approach to ensure high-quality therapy and possibly increase effects - optimizing the therapist's time in a mental health system with limited resources. VRET utilizes modern technology to enable a more refined approach to exposure therapy, also within the context of CBTp. VR refers to a computer-generated environment with different scenes and objects that appear real, making the user feel that they are immersed in and can interact with their surroundings. In a clinical setting, therapist and client may use VRET to address difficult and complex situations in a highly controlled environment, in real time, eliciting responses equivalent to those in a real situation. The objective is to habituate learned fear responses or disprove catastrophic beliefs held by the client. VR provides ample opportunity to repeatedly challenge fears and beliefs first-hand, instead of addressing them through conversation in a classic therapeutic setting (later). VRET has been found to be a well-tolerated, safe treatment method without adverse effects in individuals with psychosis. Studies examining the effect of VR therapy on social skills and VR augmented CBT in individuals with social anxiety and paranoid thoughts indicate higher motivational levels, symptom and social skills improvements and reduced social avoidance. Combined with CBT, VR also reduced social anxiety and paranoia. Another potential benefit of VRET in psychosis treatment is the possibility of easing patients into situations they would otherwise find too frightening and consequently avoid In the large UK based RCT gameChange, VR therapy led to significant reductions in distress and anxious avoidance in and of real-world situations in patients with psychosis.
RecoVRy - a new and improved Artificial Intelligence powered VR application. Based on experiences from a pilot study and important user guidance, we have developed a Norwegian VR application, RecoVRy, for individuals with psychosis experiencing anxiety in everyday social situations. Scenarios include public transportation, a waiting room, a job interview, giving a presentation in a work/educational setting, meeting with a case manager at the welfare services (NAV) and visiting a cafe. Clients are guided through scenarios by integrated instructions (orally or written) and gamification elements introducing psychological principles and aims of the treatment throughout each session. In the different scenarios, tasks are carried out, such as ordering a coffee or interacting with other passengers on the bus. RecoVRy is designed to be easy to use, engaging for patients and clinicians and delivered with the latest consumer equipment. Additionally, RecoVRy combines VR with state of the art Artificial Intelligence (AI) to further increase immersion and potentially strengthen effects of behavioural activation and exposure. In most VR applications, including gameChange, patients cannot interact with avatars (e.g. customers in a shop or other passengers on a bus). Regardless of what the patient does or says during session, the avatars will provide standard comments and replies, not necessarily fitting the situation. Experiences from the pilot study indicated a strong need for patients to be able to interact with avatars across the scenarios. AI elements thus contribute to move the VR field forward and have been included in the RecoVRy application. No previous large studies have described or examined the combined usage of these two emerging technologies in psychosis treatment. Each scenario has several difficulty levels and is designed to activate fearful cognitions, enabling patients to explore fears and paranoid thoughts, and trying new behaviors while at the same time limit the use of defence mechanisms and avoidance. Events take place that challenge patients to drop safety-seeking behaviors they normally use, with the ultimate goal of helping them adopt new behaviors to use when feeling anxious and consequently feel more confident in everyday situations. Each session lasts approximately 30 minutes. RecoVRy entails CBT components. Consequently, it is not required for CBT trained staff to deliver the therapy. RecoVRy represents a completely new way of delivering psychosis treatment and has never been tested in Norway, that is, the new AI powered scenarios have been tested in a small clinical pilot for acceptability testing and technical verification (N = 5). In the current study, the aim is to determine the effect on real-world functioning, psychiatric symptoms and quality of life in individuals with psychosis. Further, the investigators will establish barriers and facilitators with regard to the implementation of VR therapy in clinical practice through a qualitative sub-study in patients, clinicians and health care leaders/stakeholders. A health economic evaluation of RecoVRy will also be carried out.
This study will answer whether using AI powered VR in psychosis treatment results in improved health and functional outcomes, and whether this technology increases access to augmented CBT in patients with schizophrenia by adding specific components of CBTp. RecoVRy may shorten the length of treatment, saving time and cost. Findings from this study will be relevant for public and private mental health services in Norway and internationally on the implementation of technology-based interventions in psychosis RecoVRy will create potential for improvement of existing practise and personalized treatment. CBTp, including central components such as behavioral experiments and exposure, is well-established. However, far from every mental health professional has CBT training, and behavioral experiments and exposure are often too time-consuming to be implemented in clinical practice. Consequently, many patients do not receive CBT at all, or when receiving CBT, are not given the opportunity to expose themselves to situations causing anxiety under clinical guidance. The use of RecoVRy can help overcome these challenges and may increase treatment effects by using AI to further tailor exposure. It can be used both as stand-alone treatment and as an add-on to CBTp, ensuring treatment access for more people and the ability to provide safe and effective exposure and behavioral tests under clinical guidance. RecoVRy thus touches upon the prioritized thematic area of new ways of working and several clinical groups and personnel can deliver VR treatment. Moreover, studies have shown that learning occurring through VRET transfers to the real-world, i.e. what you overcome in VR, you overcome in real life, which is not always the case with classic, dialogue-based CBTp.
RecoVRy will fill knowledge gaps concerning treatment of anxiety in psychosis. Recent reviews and meta-analyses call for further development and customization of CBT in terms of personalized psychotherapy. Actively entering anxiety provoking situations and practicing more adapting ways of thinking and behaving is challenging in face-to-face therapy, but relatively easy in VRET. Thus far, only a handful of studies, with promising results, have examined the impact of VRET on severe mental disorders. None has examined the effect of VRET combined with AI. Experience from the computer game industry suggests that VR-assisted therapies can be much more enjoyable than traditional treatments, ensuring good take-up and continuous "use" of the therapy. Further research is thus warranted. The current RCT aims to explore if the positive outcomes from using VRET can be repeated in individuals with psychosis using a Norwegian application and whether this treatment is cost effective. Evidence from this study will be of scientific interest nationally and internationally. RecoVRy will create societal benefits. Based on the assumption that a substantial part of the social avoidance and inactivity in schizophrenia arises from anxiety, using AI powered VR as a new medium for therapy may be a good first-step for individuals who have avoided mental health care in the past. It is well-known from the field of social anxiety disorder that appropriate treatment may produce superior results, provided the treatment is actually offered. RecoVRy may increase treatment adherence, as it might be more appealing than traditional methods, encouraging patients to continue therapy. It ensures consistency - the same treatment program is offered to all users, with the possibility of tailoring according to individual needs. RecoVRy can help shorten the length of treatment, will cost less than traditional therapy and can help therapists provide treatment to individuals at their convenience. Most importantly, social inclusion and self-governance are of high societal and individual value. Overcoming symptoms of anxiety may directly translate to greater social, educational and occupational participation - reducing costs and creating benefits.
Knowledge from RecoVRy can easily be generalized to other populations and health sectors. RecoVRy is thoroughly described and will be manualized when completed. The knowledge gained from this study, combined with already existing material based on VR for psychosis, will make it easy to generalize the knowledge and practicalities to other patient populations, age groups and health sectors. It will be particularly relevant for disorders in which social anxiety and withdrawal strongly contribute to the clinical consequences, such as phobias, mood disorders and other anxiety disorders.
Our hypothesis is that RecoVRy combined with Treatment as Usual (TAU) is superior to VR gaming and TAU and leads to post treatment improvements in anxiety, avoidance, psychotic symptoms, depression, worry, paranoia, insight, quality of life and social/functional activity. A working hypothesis is that RecoVRy is superior to the control group in terms of cost-effectiveness.
Primary and secondary endpoints The primary endpoint will be the Cognitions and Defence Behaviours Questionnaire (CDBQ), a clinically meaningful measure assessing worries, avoidance and ability to manage different social situations. Analyses will include all participants for whom data are available and according to the group participants are randomly assigned to, regardless of any deviation from protocol. Analyses will be carried out after the last follow-up assessment is completed with no interim analyses and CDBQ will be assessed at all time points.
The secondary endpoints; i) Changes in mean scores of anxiety, positive and negative psychotic symptoms, work and social adjustment, quality of life, social functioning, depressive symptoms, worry, paranoia, insight, hope and neurocognition in both groups ii) group differences in health care utilization/health economy Safety outcomes and therapy satisfaction will be assessed using the Simulator Sickness Questionnaire and The Therapy Satisfaction Scale at post assessment The RecoVRy intervention Patients will be electronically randomized to either RecoVRy + TAU or TAU. The intervention group will receive eight VR sessions of 30 minutes. Three sessions are considered minimum dose of therapy. A mental health professional (VR therapist) will be present when VR treatment is provided and will help put on the VR headset, start the program and encourage the patient to apply the learning from RecoVRy to real-world challenges by setting up homework tasks to be carried out between VR sessions. The application will run through Meta Quest 2/3®. RecoVRy is designed as a repeated behavioural procedure in which the main focus is for participants to learn that they are safer than assumed. Participants can proceed at their own pace, allowing for more or less than 8 (+/- 2) sessions of VR treatment. Scenarios and levels may be repeated if necessary.
Statistical analysis Statistical analysis will be carried out according to the intention-to-treat (ITT) principle. The primary and secondary outcomes will be analyzed using linear mixed-effects regression to model post-test and follow-up assessments concurrently. In addition, structural equation models and linear regression will be applied to examine potential mediators and moderators with regard to VR therapy. Statistical power estimates:100 participants will be enrolled, 50 in each group. This sample size takes into consideration an attrition rate of 10% and provides 80% power to detect clinically significant differences in the CDBQ from randomization to 8 weeks at a two-sided 5% significance level.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to this arm will receive CBT assisted artificial intelligence driven Virtual Reality therapy for a total of ten sessions.
Behavioral: RecoVRy
Patients in the control group will receive ten sessions of different virtual reality games.
Behavioral: VR Games
A mental health professional (VR therapist) will be together with the patient when VR treatment is provided. The VR therapist will help put on the VR headset, start the program and encourage the patient to apply the learning from RecoVRy to real-world challenges by setting up homework tasks to be carried out between VR sessions. The application will run through Meta Quest 2/3®. RecoVRy is designed as a repeated behavioural procedure in which the main focus is for participants to learn that they are safer than assumed. Participants can proceed at their own pace, allowing for more or less than 8 (+/- 2) sessions of VR treatment. Scenarios and levels may be repeated if necessary
Patients randomized to this condition will receive a total of ten sessions of VR games.
Oxford Cognitions and Defences Questionnaire (O-CDQ)
The O-CDQ consists of three subscales: threat cognitions (14 items), anxious avoidance (11 items), and within-situation safety behaviours (8 items). And one total score. The range of scores goes from 0-102. Higher scores mean worse outcome
Time frame: From enrollment to the end of treatment at ten weeks.
Oxford Cognitions and Defences Questionnaire
The O-CDQ consists of three subscales: threat cognitions (14 items), anxious avoidance (11 items), and within-situation safety behaviours (8 items). And one total score. The range of scores goes from 0-102. Higher scores mean worse outcome.
Time frame: From enrollment to follow-up at 26 weeks
The Oxford Agoraphobic Avoidance Scale (O-AS)
This questionnaire is all about anxiety in everyday situations and consists of seven items scored from 0-10. The total scale is scored from 0-70 and higher scores mean worse outcome.
Time frame: From enrollment to the end of treatment at ten weeks.
The Oxford Agoraphobic Avoidance Scale (O-AS)
This questionnaire is all about anxiety in everyday situations and consists of seven items scored from 0-10. The total scale is scored from 0-70 and higher scores mean worse outcome.
Time frame: From enrollment to follow-up at 26 weeks
Positive and Negative Syndrome Scale-6
Asses positive and negative symptoms and consists of six items scored from 1-7. Higher scores mean worse outcome.
Time frame: From enrollment to the end of treatment at ten weeks.
Positive and Negative Syndrome Scale-6
Asses positive and negative symptoms and consists of six items scored from 1-7. Higher scores mean worse outcome.
Time frame: From enrollment to follow-up at 26 weeks
General Anxiety Disorder-7 (GAD-7)
Measure levels of anxiety and consists of seven items scored between 0 and 3. The total scores are from 0-21 and higher scores indicates worse outcome.
Time frame: From enrollment to the end of treatment at ten weeks.
General Anxiety Disorder-7 (GAD-7)
Measure levels of anxiety and consists of seven items scored between 0 and 3. The total scores are from 0-21 and higher scores indicates worse outcome.
Time frame: From enrollment to follow-up at 26 weeks
Beck Depression Inventory II
Measure symptoms of depression the last week and consists of 21 items scored between 0 and 3. The total scores are between 0 and 63 and higher score indicates worse outcome.
Time frame: From enrollment to the end of treatment at ten weeks.
Beck Depression Inventory II
Measure symptoms of depression the last week and consists of 21 items scored between 0 and 3. The total scores are between 0 and 63 and higher score indicates worse outcome.
Time frame: From enrollment to follow-up at 26 weeks
Work and Social Adjustment Scale
Assess level of functioning and work capacity the last two weeks and consists of 5 items scored between 0 and 8. The total scores are between 0 and 40 and higher score indicates worse outcome.
Time frame: From enrollment to the end of treatment at ten weeks.
Work and Social Adjustment Scale
Assess level of functioning and work capacity the last two weeks and consists of 5 items scored between 0 and 8. The total scores are between 0 and 40 and higher score indicates worse outcome.
Time frame: From enrollment to follow-up at 26 weeks
Beck Cognitive Insight Scale (BCIS)
Assess level of insight into the patients own illness and consists of 15 items scored between 0 and 3. The total score range from 0 to 45 and higher score indicates worse outcome.
Time frame: From enrollment to the end of treatment at ten weeks.
Beck Cognitive Insight Scale (BCIS)
Assess level of insight into the patients own illness and consists of 15 items scored between 0 and 3. The total score range from 0 to 45 and higher score indicates worse outcome.
Time frame: From enrollment to follow-up at 26 weeks
Bergen Insomnia Scale (BIS)
Measure level of problems with sleep and consists of 6 items scored between 0 and 7. They indicate how many days a sleep problem exists during the week. The total score is between 0 and 42. Higher score indicated worse outcome.
Time frame: From enrollment to the end of treatment at ten weeks.
Bergen Insomnia Scale (BIS)
Measure level of problems with sleep and consists of 6 items scored between 0 and 7. They indicate how many days a sleep problem exists during the week. The total score is between 0 and 42. Higher score indicated worse outcome.
Time frame: From enrollment to follow-up at 26 weeks
Manchester Short Assessment of quality of Life (MANSA)
Assess the level of subjective quality of life reported by the patients. The instrument consists of 16 items scores between 1 and 7. The scores are between 16 and 112. Higher scores indicate better quality of life.
Time frame: From enrollment to the end of treatment at ten weeks.
Manchester Short Assessment of quality of Life (MANSA)
Assess the level of subjective quality of life reported by the patients. The instrument consists of 16 items scores between 1 and 7. The scores are between 16 and 112. Higher scores indicate better quality of life.
Time frame: From enrollment to follow-up at 26 weeks
Perceived Stress Scale (PSS)
Assess the patients reported level of stress and consist of 10 items scores between 0 and 4. The total score is between 0 and 40 and higher score indicates worse outcome.
Time frame: From enrollment to the end of treatment at ten weeks.
Perceived Stress Scale (PSS)
Assess the patients reported level of stress and consist of 10 items scores between 0 and 4. The total score is between 0 and 40 and higher score indicates worse outcome.
Time frame: From enrollment to follow-up at 26 weeks
Domain Specific Hope Scale (DSHS)
DSHS scale is designed to assess hope in specific life arenas. Each domain comprise 8 items scored from 1 and 8. Higher scores indicates better outcome.
Time frame: From enrollment to the end of treatment at ten weeks.
Domain Specific Hope Scale (DSHS)
DSHS scale is designed to assess hope in specific life arenas. Each domain comprise 8 items scored from 1 and 8. Higher scores indicates better outcome.
Time frame: From enrollment to follow-up at 26 weeks
Oxford Depression Questionnaire (ODQ)
Measure depressive symptoms with an emphasis on anhedonia. It consists of two parts. 1. Part one is emotional reaction and consists of 12 items and part two which assess changes in emotional reactions here and now and also consist of 8 items. The items are scores from 0-4 and higher scores indicate worse outcome.
Time frame: From enrollment to the end of treatment at ten weeks.
The Oxford Depression Questionnaire (ODQ)
Measure depressive symptoms with an emphasis on anhedonia. It consists of two parts. 1. Part one is emotional reaction and consists of 12 items and part two which assess changes in emotional reactions here and now and also consist of 8 items. The items are scores from 0-4 and higher scores indicate worse outcome.
Time frame: From enrollment to follow-up at 26 weeks
Questionnaire about the Process of Recovery (QPR)
The QPR measure patients thought about the recovery process and consists of 22 items scored for 0-4. Higher scores indicate better outcome.
Time frame: From enrollment to the end of treatment at ten weeks.
The Questionnaire about the Process of Recovery
The QPR measure patients thought about the recovery process and consists of 22 items scored for 0-4. Higher scores indicate better outcome.
Time frame: From enrollment to follow-up at 26 weeks
EQ-5D-5L
Concise generic instrument for measuring patients' self-reported health and compises 5 items from 0-100. Higher score indicated better outcome.
Time frame: From enrollment to the end of treatment at ten weeks.
EQ-ED-5L
Concise generic instrument for measuring patients' self-reported health and compises 5 items from 0-100. Higher score indicated better outcome.
Time frame: From enrollment to follow-up at 26 weeks
Working Alliance Inventory-12 Patient version
Assess the alliance between therapist and patient and consists of 12 items. Higher scores indicate better alliance.
Time frame: From enrollment to week three.
The Working Alliance Inventory- 12 Therapist Version
Assess the alliance between therapist and patient and consists of 12 items. Higher scores indicate better alliance.
Time frame: From enrollment to week three.
Not enrolling at this site.
Plan to share: No — We have not decided how to share data at this point. Data will be shared anonymized on request to the PI
Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.
Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 36 months is close to that.
Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.